Complement Activation in Patients With Congestive Heart Failure Effect of High-Dose Intravenous Immunoglobulin Treatment

• Published in: Circulation (New York, N.Y.) Vol. 104; no. 13; pp. 1494 - 1500
• Main Authors: Aukrust, Pål, Gullestad, Lars, Lappegård, Knut T., Ueland, Thor, Aass, Halfdan, Wikeby, Lisbeth, Simonsen, Svein, Frøland, Stig S., Mollnes, Tom E.
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 25.09.2001; American Heart Association, Inc
• Subjects: Biological and medical sciences; C-Reactive Protein - drug effects; C-Reactive Protein - metabolism; Cardiology. Vascular system; Complement Activation - drug effects; Female; Heart; Heart Failure - drug therapy; Heart Failure - immunology; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Immunoglobulins, Intravenous - therapeutic use; Male; Medical sciences; Middle Aged; Sinus of Valsalva - immunology; Stroke Volume - drug effects; Human; Heart failure; Immunoglobulins; Intravenous administration; Leukocyte; Pathogenesis; Heart disease; Cardiovascular disease; Activation; Complement; Inflammation
• ISSN: 0009-7322; 1524-4539; 1524-4539
• DOI: 10.1161/hc3801.096353

Background Increasing evidence implicates innate immunity in the pathogenesis of congestive heart failure (CHF). In the present study, we examined the possible role of complement, an important part of innate immunity, in CHF. Methods and Results Complement activation was analyzed in systemic and coronary circulation in 39 patients with CHF and 20 healthy control subjects. In a double-blind, placebo-controlled study, we have recently reported that high-dose intravenous immunoglobulin (IVIG) improves left ventricular ejection fraction (LVEF) in these patients. To examine if this improvement was related to IVIG-induced effects on complement, we also examined complement activation during induction (first week) and maintenance therapy (6 months) with IVIG or placebo. Our main findings were: (1) We found enhanced systemic complement activation involving classic, alternative, as well as terminal pathway in patients with CHF compared with healthy control subjects. (2) Particularly enhanced complement activation was found in coronary sinus, representing venous drainage from the heart. (3) The systemic complement activation was further enhanced during IVIG but not during placebo therapy, particularly during induction therapy. (4) Although IVIG improved LVEF in patients with CHF, the degree of IVIG-mediated complement activation was negatively correlated with this improvement of LVEF. Conclusions This study further supports the involvement of innate immunity in the pathogenesis of CHF. Our findings suggest that complement may be added to the list of possible therapeutic targets in CHF and that future studies with specific complement inhibitors may be of interest in this disorder.